GlassScriptPhysician profile
Prathima Jasti
NPI 1699971473
$1,183.88
in general payments reported to CMS, 2019-2025
20 companies · $308 in 2025
The $308 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $241 · 2021: $74.92 · 2022: $114 · 2023: $144 · 2024: $188 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $640.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $360.26 | 2019-2025 | Ozempic, Rybelsus |
| Tandem Diabetes Care, INC. | $100.21 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic, INC. | $93.53 | 2021-2024 | Minimed 780g |
| Dexcom, INC. | $89.19 | 2019-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $72.18 | 2019-2025 | Tepezza, Evenity, Prolia |
| Insulet Corporation | $62.56 | 2019-2022 | |
| Corcept Therapeutics | $60.12 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.92 | 2023-2024 | Jardiance |
| Lilly USA, LLC | $40.61 | 2019-2023 | Baqsimi, Jardiance |
| Astrazeneca Pharmaceuticals LP | $36.07 | 2020-2024 | Farxiga |
| Xeris Pharmaceuticals, INC. | $34.60 | 2022-2024 | Gvoke Hypopen |
| Medtronic Minimed, INC. | $31.42 | 2020 | |
| Ascendis Pharma Endocrinology INC | $28.41 | 2024-2025 | Yorvipath |
| Abbvie INC. | $24.01 | 2020 | |
| Abbott Laboratories | $23.30 | 2025 | Freestyle Libre 3 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $22.81 | 2025 | Ibsrela |
| Beta Bionics, INC. | $13.37 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Amryt Pharma Holdings LTD | $13.13 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.11 | 2021 | |
| Tolmar, INC. | $13.07 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Prathima Jasti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.